| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 9
| Issue : 1 | Page : 31-36 |
|
|
Antischistosomal activity of Mirazid in experimental schistosomiasis mansoni: exploring the controversy
Mohammad A Al-Kazzaz MSc , Mona H El-Sayad, Sahar A Abu-Helw
Department of Parasitology, Medical Research Institute, Alexandria University, Alexandria, Egypt
Correspondence Address:
Mohammad A Al-Kazzaz
27 Street, 15 Al-Awayed, Alexandria
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1687-7942.192993
|
|
|
Background
Mirazid (MZD) was licensed in Egypt for treatment of schistosomiasis in the year 2002; the drug gained much attention experimentally and clinically, with conflicting views on its efficacy.
Objective
The study aimed to evaluate MZD anti-schistosomal activity in an animal model at a selected dose.
Materials and methods
Swiss albino mice (n=36) were infected with Schistosoma mansoni and divided into two equal groups of 18 mice each: group 1 was the nontreated infected control group given only the vehicle; gourp 2 was infected and treated with MZD at a dose of 500 mg/kg for 5 days per os 7 weeks postinfection. Efficacy of the drug was assessed parasitologically with fecal egg counts evaluated every other day until the animal was euthanized at 1, 2, and 4 weeks post-treatment (WPT); worm burden, tissue egg count and oogram pattern were studied at 1, 2, and 4 WPT.
Results
MZD reduced fecal egg counts in infected mice (69.6%) and reduced total worm load (71.9%) and tissue egg counts in the intestine and the liver (66 and 77.4%, respectively) at 4 WPT. The drug changed oogram pattern with progress of treatment.
Conclusion
MZD has moderate antischistosomal activity in animal models. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
